RxDoctor Payments Data

Michael Gibson, MD

Cardiovascular Disease · Orange, CANPI 1881920882

Payments from drug & device makers

$21,072in general payments, 2019–2025

Across 89 payments — averaging $236.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$17K
  • Abiomed$2K
  • Regeneron$710
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$442
  • Boehringer Ingelheim$421
  • Cvrx, Inc.$183
  • plus $746 from 13 others

What the payments were for

  • Consulting fees$1,91325%
  • Travel & lodging$7109%
  • Food & beverage$5,08665%
  • Education$821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,072 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$142,371
Medicare patients
269
Services billed
1,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis37$1,327,271
JardianceEmpagliflozin300$407,703
EntrestoSacubitril/Valsartan300$361,964
EliquisApixaban125$165,848
FarxigaDapagliflozin Propanediol52$64,041
OzempicSemaglutide63$61,883
Ambrisentan18$35,627
XareltoRivaroxaban13$20,246
VerquvoVericiguat13$18,382
Repatha SureclickEvolocumab15$9,066
Bumetanide136$7,213
Metoprolol Succinate234$4,382
Spironolactone283$2,802
Rosuvastatin Calcium74$1,727
Eplerenone22$1,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$421$407,703300 claims
NovartisEntresto$18$361,964300 claims
Novo NordiskOzempic$104$61,88363 claims
MerckVerquvo$56$18,38213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →